· Trials · Trials Desk
ATTAIN and ACHIEVE programs make orforglipron the first small-molecule oral obesity drug to deliver injection-comparable weight loss without a peptide backbone. NCT05869903, NCT05971940.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.